Fears of diabetes drugs crackdown
Clinicians are concerned a looming crackdown on prescribing diabetes drugs could see Australia "falling behind the rest of the world" in diabetes management.
The latest stage in the Pharmaceutical Benefits Advisory Committee's ongoing review of the drugs has flagged concerns about inappropriate use of costly newer medications such as the gliptins and exenatide.
The review said a "large proportion" of PBS prescriptions for gliptins did not meet current criteria for PBS subsidies. These restrict the drugs' use to patients who are unable to